The report “Microbiology Testing/Clinical Microbiology Market by Application (Pharma, Clinical, Manufacturing, Environment), Disease (Respiratory Disease, STD, UTI), Product (Instrument, Analyzer, Reagent), End User (Hospital, Diagnolab, Academia) – Global Forecast to 2023″, The global clinical microbiology market is expected to reach USD 4.95 billion by 2023 from USD 3.63 billion in 2018, at a CAGR of 6.4%.

The major factors driving the growth of the clinical microbiology market include technological advancements in the field of infectious disease diagnostics, rising incidence and prevalence of infectious diseases and growing outbreak of epidemics, and the increased funding and public-private investments for the development of novel products for infectious disease diagnosis.

North America is expected to dominate the clinical microbiology market in 2018

Geographically, the market is segmented into North America (the US and Canada), Europe (Germany, the UK, France, and the Rest of Europe), Asia Pacific (Japan, China, India, and the Rest of APAC), and the Rest of the World (Latin America, and the Middle East and Africa). North America is expected to account for the largest share of the global clinical microbiology market in 2018 due to easy accessibility and high adoption of advanced diagnostic techniques, technological advancements in microbial testing techniques, rising geriatric population, and growing public-private funding to support microbiology-based research in the region.

Download Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=219135367

• Pharmaceutical applications are expected to dominate the microbiology testing market in 2018
• Laboratory instruments are projected to hold the largest share of the clinical microbiology instruments market in 2018
• Respiratory diseases are expected to be the largest diseases area in clinical microbiology market in 2018

The major players operating in the microbiology testing/clinical microbiology market include bioMérieux SA (France), Danaher Corporation (US), Becton, Dickinson and Company (US), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Bruker Corporation (US), Hologic, Inc. (US), QIAGEN N.V. (The Netherlands), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Shimadzu Corporation (Japan), 3M Company (US), and Neogen Corporation (US), among others.

bioMérieux S.A. (France) held the leading position in the global clinical microbiology market in 2017. The company has a robust product portfolio and a strong geographical presence in more than 150 countries across the world. To maintain its leadership position in the market, the company has been focusing on R&D activities and product launches.

Danaher Corporation (US) held the second position in the global clinical microbiology market in 2017. The company operates in the clinical microbiology testing market through its wholly owned subsidiaries- Beckman Coulter and Cepheid. Danaher is focusing on strengthening its position in the global clinical microbiology market mainly by adopting strategies such as acquisitions and new product launches. The acquisition of Beckman Coulter Inc. (a major player in the US life sciences and diagnostics market) in June 2011 helped the company strengthen its product portfolio and increase its share in the clinical microbiology testing market.

Know the insights: https://www.marketsandmarkets.com/ResearchInsight/microbiology-testing-market.asp